BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 31053152)

  • 1. Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.
    Yang K; Guo W; Ren T; Huang Y; Han Y; Zhang H; Zhang J
    J Exp Clin Cancer Res; 2019 May; 38(1):185. PubMed ID: 31053152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of MSI2 inhibits metastasis by interacting with caveolin-1 and inhibiting its ubiquitylation in human NF1-MPNST cells.
    Yang K; Du J; Shi D; Ji F; Ji Y; Pan J; Lv F; Zhang Y; Zhang J
    Cell Death Dis; 2020 Jun; 11(6):489. PubMed ID: 32606289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Williams KB; Largaespada DA
    Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
    Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
    Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms.
    Reuss DE; Habel A; Hagenlocher C; Mucha J; Ackermann U; Tessmer C; Meyer J; Capper D; Moldenhauer G; Mautner V; Frappart PO; Schittenhelm J; Hartmann C; Hagel C; Katenkamp K; Petersen I; Mechtersheimer G; von Deimling A
    Acta Neuropathol; 2014 Apr; 127(4):565-72. PubMed ID: 24464231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
    Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
    Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation.
    Hirbe AC; Dahiya S; Friedmann-Morvinski D; Verma IM; Clapp DW; Gutmann DH
    Oncotarget; 2016 Feb; 7(7):7403-14. PubMed ID: 26859681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-27a-3p/miR-27b-3p Promotes Neurofibromatosis Type 1 via Targeting of NF1.
    Lu H; Liu P; Pang Q
    J Mol Neurosci; 2021 Nov; 71(11):2353-2363. PubMed ID: 33570696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
    Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
    PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
    Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics.
    Sugita S; Aoyama T; Emori M; Kido T; Takenami T; Sakuraba K; Terai K; Sugawara T; Tsujiwaki M; Hasegawa T
    Diagn Pathol; 2021 Aug; 16(1):79. PubMed ID: 34461930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.
    Lemberg KM; Wang J; Pratilas CA
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32599735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.
    Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M
    J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs.
    Miller DT; Cortés-Ciriano I; Pillay N; Hirbe AC; Snuderl M; Bui MM; Piculell K; Al-Ibraheemi A; Dickson BC; Hart J; Jones K; Jordan JT; Kim RH; Lindsay D; Nishida Y; Ullrich NJ; Wang X; Park PJ; Flanagan AM
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32252413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
    Dang I; DeVries GH
    J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.